1. In Vivo
  2. >>Growth

LivaNova Builds Strategic Base And Commercial Case To Silence Skeptics

 
• By Ashley Yeo

Medical innovator LivaNova has a new stated focus: it won’t go outside the head and the heart when it comes to potential M&A and technology development projects. It has set out short- and longer-term solutions to boost sales and/or profitability in its neuromodulation and cardio franchises. What is certain is that eight months into his tenure as CEO, Damien McDonald is stamping his imprint all over LivaNova.

livanova

LivaNova PLC’s twin-continent Investor Day road show in September was an illustration of how far the UK-registered company has come in a short time. And how much it has changed under the leadership of former Danaher executive Damien McDonald. With the backing of a supportive board, McDonald, whose CV includes a range of top medtech jobs in a 25-year industry career, has put in place strategic business and key staff changes that are designed to give a strong sense of certainty to health-care sector stakeholders and shareholders.

“Certainty” is a big word in the McDonald corporate vocabulary, as analysts and investors at the London leg of the LivaNova road show learned

Developing the promising-but-underleveraged opportunities of the two – now one – legacy high-risk medtech product developers has been McDonald’s focus since assuming the CEO role in January.(Also see "Cardio-Neuro Innovator LivaNova Prepares For Challenges Ahead" - In Vivo, 29 March, 2017

More from Growth

More from In Vivo

NewAmsterdam’s Davidson On Reviving “Failed” Drug Class To Fill Cardiovascular Treatment Gap

 
• By David Wild

After a string of high-profile failures by big pharma, Michael Davidson is positioning his company's CETP inhibitor as the next breakthrough in cardiovascular medicine. The body of data to support this position is growing.

Rising Leaders 2025: Flagship’s Jacob Rubens On Building The Next Generation Of Biotech

 
• By David Wild

Rising Leader Jacob Rubens, who has co-founded and led several Flagship companies and is now origination partner, believes aspiring leaders should follow their bliss.

Dealmaking Quarterly Statistics, Q1 2025

 
• By Deanna Kamienski and Maureen Riordan

During Q1, biopharma M&A deal value reached $38.4bn and drew in $60.8bn in potential deal value from alliances. Device company M&A values reached $8.7bn.